Clinical Trials Browser

Phase 1 × necitumumab × 90 days × Clear all

NCT02496663 2026-05-13

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms